Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients

Outi Kilpivaara, Jirina Bartkova, Hannaleena Eerola, Kirsi Syrjäkoski, Pia Vahteristo, Jiri Lukas, Carl Blomqvist, Kaija Holli, Päivi Heikkilä, Guido Sauter, Olli Kallioniemi, Jiri Bartek, Heli Nevanlinna (Corresponding Author)

    Research output: Contribution to journalArticleScientificpeer-review

    84 Citations (Scopus)

    Abstract

    The CHEK2 kinase is a tumor suppressor whose activation in response to DNA double‐strand breaks contributes to cell cycle arrest or apoptosis. The c.1100delC mutation is associated with familial breast cancer, and tumors from mutation carriers show reduced or absent CHEK2 protein expression. We have here studied CHEK2 protein expression by immunohistochemistry on a tissue microarray of 611 unselected breast tumors and also evaluated the tumor characteristics among 1,297 unselected breast cancer patients defined for the c.1100delC germ line mutation status (2.5% carrier frequency). CHEK2 protein expression was reduced in 21.1% of the unselected breast cancers studied. Tumors with reduced CHEK2 expression had more often larger primary tumor size (pT3–4; nominal significance p = 0.002) compared to tumors with normal staining. A similar trend for larger tumor size was seen among the 37 breast tumors from c.1100delC germ line mutation carriers. Tumors from c.1100delC mutation carriers were of higher grade than those of noncarriers (nominal significance p = 0.02). The c.1100delC germ line mutation also associated strongly with bilateral breast cancer. No significant correlation was seen between CHEK2 status and hormone receptor status, histology, lymph node status, or overall survival.
    Original languageEnglish
    Pages (from-to)575 - 580
    Number of pages6
    JournalInternational Journal of Cancer
    Volume113
    Issue number4
    DOIs
    Publication statusPublished - 2005
    MoE publication typeA1 Journal article-refereed

    Fingerprint

    Breast Neoplasms
    Mutation
    Germ-Line Mutation
    Neoplasms
    Proteins
    Checkpoint Kinase 2
    DNA Breaks
    Cell Cycle Checkpoints
    Histology
    Lymph Nodes
    Immunohistochemistry
    Hormones
    Apoptosis
    Staining and Labeling
    Survival

    Keywords

    • CHEK2
    • tumor characteristics
    • breast cancer

    Cite this

    Kilpivaara, O., Bartkova, J., Eerola, H., Syrjäkoski, K., Vahteristo, P., Lukas, J., ... Nevanlinna, H. (2005). Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. International Journal of Cancer, 113(4), 575 - 580. https://doi.org/10.1002/ijc.20638
    Kilpivaara, Outi ; Bartkova, Jirina ; Eerola, Hannaleena ; Syrjäkoski, Kirsi ; Vahteristo, Pia ; Lukas, Jiri ; Blomqvist, Carl ; Holli, Kaija ; Heikkilä, Päivi ; Sauter, Guido ; Kallioniemi, Olli ; Bartek, Jiri ; Nevanlinna, Heli. / Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. In: International Journal of Cancer. 2005 ; Vol. 113, No. 4. pp. 575 - 580.
    @article{7e208206b8164e009d8b2f9ed17d8a36,
    title = "Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients",
    abstract = "The CHEK2 kinase is a tumor suppressor whose activation in response to DNA double‐strand breaks contributes to cell cycle arrest or apoptosis. The c.1100delC mutation is associated with familial breast cancer, and tumors from mutation carriers show reduced or absent CHEK2 protein expression. We have here studied CHEK2 protein expression by immunohistochemistry on a tissue microarray of 611 unselected breast tumors and also evaluated the tumor characteristics among 1,297 unselected breast cancer patients defined for the c.1100delC germ line mutation status (2.5{\%} carrier frequency). CHEK2 protein expression was reduced in 21.1{\%} of the unselected breast cancers studied. Tumors with reduced CHEK2 expression had more often larger primary tumor size (pT3–4; nominal significance p = 0.002) compared to tumors with normal staining. A similar trend for larger tumor size was seen among the 37 breast tumors from c.1100delC germ line mutation carriers. Tumors from c.1100delC mutation carriers were of higher grade than those of noncarriers (nominal significance p = 0.02). The c.1100delC germ line mutation also associated strongly with bilateral breast cancer. No significant correlation was seen between CHEK2 status and hormone receptor status, histology, lymph node status, or overall survival.",
    keywords = "CHEK2, tumor characteristics, breast cancer",
    author = "Outi Kilpivaara and Jirina Bartkova and Hannaleena Eerola and Kirsi Syrj{\"a}koski and Pia Vahteristo and Jiri Lukas and Carl Blomqvist and Kaija Holli and P{\"a}ivi Heikkil{\"a} and Guido Sauter and Olli Kallioniemi and Jiri Bartek and Heli Nevanlinna",
    year = "2005",
    doi = "10.1002/ijc.20638",
    language = "English",
    volume = "113",
    pages = "575 -- 580",
    journal = "International Journal of Cancer",
    issn = "0020-7136",
    publisher = "Wiley",
    number = "4",

    }

    Kilpivaara, O, Bartkova, J, Eerola, H, Syrjäkoski, K, Vahteristo, P, Lukas, J, Blomqvist, C, Holli, K, Heikkilä, P, Sauter, G, Kallioniemi, O, Bartek, J & Nevanlinna, H 2005, 'Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients', International Journal of Cancer, vol. 113, no. 4, pp. 575 - 580. https://doi.org/10.1002/ijc.20638

    Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. / Kilpivaara, Outi; Bartkova, Jirina; Eerola, Hannaleena; Syrjäkoski, Kirsi; Vahteristo, Pia; Lukas, Jiri; Blomqvist, Carl; Holli, Kaija; Heikkilä, Päivi; Sauter, Guido; Kallioniemi, Olli; Bartek, Jiri; Nevanlinna, Heli (Corresponding Author).

    In: International Journal of Cancer, Vol. 113, No. 4, 2005, p. 575 - 580.

    Research output: Contribution to journalArticleScientificpeer-review

    TY - JOUR

    T1 - Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients

    AU - Kilpivaara, Outi

    AU - Bartkova, Jirina

    AU - Eerola, Hannaleena

    AU - Syrjäkoski, Kirsi

    AU - Vahteristo, Pia

    AU - Lukas, Jiri

    AU - Blomqvist, Carl

    AU - Holli, Kaija

    AU - Heikkilä, Päivi

    AU - Sauter, Guido

    AU - Kallioniemi, Olli

    AU - Bartek, Jiri

    AU - Nevanlinna, Heli

    PY - 2005

    Y1 - 2005

    N2 - The CHEK2 kinase is a tumor suppressor whose activation in response to DNA double‐strand breaks contributes to cell cycle arrest or apoptosis. The c.1100delC mutation is associated with familial breast cancer, and tumors from mutation carriers show reduced or absent CHEK2 protein expression. We have here studied CHEK2 protein expression by immunohistochemistry on a tissue microarray of 611 unselected breast tumors and also evaluated the tumor characteristics among 1,297 unselected breast cancer patients defined for the c.1100delC germ line mutation status (2.5% carrier frequency). CHEK2 protein expression was reduced in 21.1% of the unselected breast cancers studied. Tumors with reduced CHEK2 expression had more often larger primary tumor size (pT3–4; nominal significance p = 0.002) compared to tumors with normal staining. A similar trend for larger tumor size was seen among the 37 breast tumors from c.1100delC germ line mutation carriers. Tumors from c.1100delC mutation carriers were of higher grade than those of noncarriers (nominal significance p = 0.02). The c.1100delC germ line mutation also associated strongly with bilateral breast cancer. No significant correlation was seen between CHEK2 status and hormone receptor status, histology, lymph node status, or overall survival.

    AB - The CHEK2 kinase is a tumor suppressor whose activation in response to DNA double‐strand breaks contributes to cell cycle arrest or apoptosis. The c.1100delC mutation is associated with familial breast cancer, and tumors from mutation carriers show reduced or absent CHEK2 protein expression. We have here studied CHEK2 protein expression by immunohistochemistry on a tissue microarray of 611 unselected breast tumors and also evaluated the tumor characteristics among 1,297 unselected breast cancer patients defined for the c.1100delC germ line mutation status (2.5% carrier frequency). CHEK2 protein expression was reduced in 21.1% of the unselected breast cancers studied. Tumors with reduced CHEK2 expression had more often larger primary tumor size (pT3–4; nominal significance p = 0.002) compared to tumors with normal staining. A similar trend for larger tumor size was seen among the 37 breast tumors from c.1100delC germ line mutation carriers. Tumors from c.1100delC mutation carriers were of higher grade than those of noncarriers (nominal significance p = 0.02). The c.1100delC germ line mutation also associated strongly with bilateral breast cancer. No significant correlation was seen between CHEK2 status and hormone receptor status, histology, lymph node status, or overall survival.

    KW - CHEK2

    KW - tumor characteristics

    KW - breast cancer

    U2 - 10.1002/ijc.20638

    DO - 10.1002/ijc.20638

    M3 - Article

    VL - 113

    SP - 575

    EP - 580

    JO - International Journal of Cancer

    JF - International Journal of Cancer

    SN - 0020-7136

    IS - 4

    ER -